Trial Profile
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2017
Price :
$35
*
At a glance
- Drugs SSR 411298 (Primary)
- Indications Cancer pain; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Sanofi
- 16 May 2014 New trial record